Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial Spotlight
Prostate cancer
Phase 1 JANX014 PSMA-directed CD3 T cell engager (tumor-activated, double-masked)
Janux Therapeutics’ first-in-human Phase 1, open-label, multicenter trial evaluates JANX014, a prostate-specific membrane antigen (PSMA)–directed CD3 T cell engager designed with “double-masking” so it is…
NCT07545811 First-in-human - New trial
Prostate cancer
Phase 2 NanoKnife IRE non-thermal ablation boost vs focal radiation boost in SBRT
Memorial Sloan Kettering Cancer Center is running this randomized Phase 2 IRRADIANT study (NCT07548164) to test whether an irreversible electroporation (IRE) “boost” to the dominant intraprostatic lesion can match a…
NCT07548164 Exploratory - New trial
Prostate cancer
Phase 2 lutetium Lu 177 vipivotide tetraxetan PSMA-targeted radioligand with EBRT in high-risk localized prostate cancer.
This Phase 2, open-label, randomized study at Johns Hopkins (Sidney Kimmel Comprehensive Cancer Center) tests whether adding lutetium Lu 177 vipivotide tetraxetan (also known as 177Lu-PSMA-617; Pluvicto, from…
NCT07550517 Exploratory - New trial
Small cell lung cancer
Phase 1b DSP-0390 EBP (cholesterol biosynthesis) inhibitor plus PD‑L1 mAb atezolizumab
This single-center Phase 1b pilot at Washington University in St. Louis tests whether adding DSP‑0390—an oral small-molecule inhibitor of emopamil-binding protein (EBP), a late-step sterol isomerase in de novo…
NCT07545954 Exploratory - New trial
Small cell lung cancer
Phase 2 PF-08634404 PD‑1×VEGF bispecific antibody with platinum-etoposide in T‑SCLC.
Pfizer’s Phase 2, open-label Symbiotic‑Lung‑14 study tests PF‑08634404, a PD‑1 and VEGF‑targeted bispecific antibody intended to combine checkpoint blockade with anti-angiogenic signaling inhibition, in adults with…
NCT07476287 Exploratory - New trial
Non-small cell lung cancer
Phase 1/2 ANS02 trial tests a 4th‑generation EGFR tyrosine kinase inhibitor.
This first-in-human, open-label, multicenter Phase 1/2 study evaluates ANS02 monotherapy in adults with locally advanced or metastatic EGFR mutation–positive non-small cell lung cancer (NSCLC), focusing on…
NCT07538804 First-in-human - New trial
Non-small cell lung cancer
Phase 2 CIMAvax‑EGF anti‑EGF vaccine plus KRAS G12C inhibitors in metastatic NSCLC
Roswell Park Comprehensive Cancer Center is running this Phase 2, open-label combination study testing whether adding CIMAvax‑EGF to an approved KRAS G12C inhibitor can improve disease control in advanced/metastatic…
NCT07543172 Exploratory - New trial
Non-small cell lung cancer
Phase 2 ateganosine (THIO) telomere-targeting nucleoside sequenced with PD-1 inhibitor cemiplimab
MAIA Biotechnology’s multicenter, open-label Phase 2 THIO-101 study tests whether ateganosine (THIO; 6‑thio‑2′‑deoxyguanosine), a telomere-targeting small-molecule nucleoside, can re-sensitize…
NCT05208944 Exploratory - New trial Spotlight
Bladder and urothelial cancer
Phase 2 enfortumab vedotin Nectin-4 ADC + pembrolizumab PD-1 inhibitor for bladder preservation.
This open-label, single-arm Phase 2 EV-209 study tests whether continuing enfortumab vedotin plus pembrolizumab can enable durable response and bladder-intact survival (including bladder intact at 2 years) in…
NCT07475806 Exploratory - New trial
Breast cancer
Phase 2 Signatera™ ctDNA MRD surveillance to time CDK4/6 inhibition (CDK4/6 cell-cycle blockade)
This prospective, single-arm, multicenter Phase 2 study from Natera tests whether ctDNA (molecular residual disease) using the tumor-informed Signatera Genome assay can guide *when* to start adjuvant CDK4/6 inhibitor…
NCT07214532 Exploratory - New trial
Breast cancer
Phase 2 inavolisib PI3Kα inhibitor + ribociclib CDK4/6 inhibitor + fulvestrant ER degrader in HR+ ABC
This Phase 2 multicenter, randomized, double-blind, placebo-controlled Roche/Genentech study tests whether adding inavolisib (a PI3Kα inhibitor) to ribociclib (a CDK4/6 inhibitor marketed by Novartis as Kisqali) plus…
NCT07405801 Exploratory - New trial
Uterine (endometrial) cancer
Phase 3 Signatera ctDNA MRD assay (tumor-informed personalized ctDNA tracking) vs vaginal brachytherapy in early endometrial cancer.
This Phase 3, randomized, multicenter study tests whether a ctDNA-guided “de-escalation” strategy after surgery is safe in Stage I high-intermediate risk endometrial cancer. Natera sponsors the trial using its…
NCT07339384 Exploratory - New trial Spotlight
Colorectal cancer
Phase 3 precemtabart tocentecan (CEACAM5 ADC delivering TOP1 inhibitor exatecan) in previously treated mCRC
This randomized, open-label, 3-arm Phase 3 study (PROCEADE-CRC-03) tests whether precemtabart tocentecan (Precem‑TcT; also known as M9140)—a CEACAM5-targeted antibody–drug conjugate that delivers the topoisomerase 1…
NCT07549412 Registrational - New trial
Colorectal cancer
Phase 2 balstilimab PD-1 mAb + botensilimab Fc‑enhanced CTLA‑4 mAb + agenT‑797 allo‑iNKT therapy
This Phase 2, open-label, single-arm study tests whether adding cellular therapy to dual checkpoint blockade can generate responses in proficient MMR (MSS/pMMR) metastatic colorectal cancer with active liver…
NCT07550088 Exploratory - New trial
Colorectal cancer
Phase 1/2 pidnarulex (RNA Pol I inhibitor, G-quadruplex stabilizer) + cemiplimab (PD-1)
This NCI-sponsored Phase 1 dose-finding plus randomized Phase 2 study tests whether adding cemiplimab (Regeneron/Sanofi’s PD-1–blocking monoclonal antibody) can improve outcomes versus pidnarulex alone in refractory…
NCT07147231 Exploratory - New trial Spotlight
Multiple myeloma
Phase 1 KLN-1010 anti-BCMA CAR gene therapy (in vivo CAR‑T generation)
This first-in-human, open-label, sequential-assignment Phase 1 trial tests KLN-1010, a one-time IV *in vivo* gene therapy intended to generate anti-BCMA CAR‑T cells inside the patient (rather than collecting and…
NCT07075185 First-in-human - New trial
Multiple myeloma
Phase 2 inobrodib (CCS1477) p300/CBP bromodomain inhibitor with Pd in R/R myeloma.
This Phase 2, open-label, multicenter, single-arm study (no comparator) evaluates inobrodib in combination with pomalidomide and dexamethasone (often described as “InoPd”) in heavily pretreated relapsed/refractory…
NCT07096778 Exploratory - New trial
Multiple myeloma
Phase 1 PF-07994525 trial in R/R multiple myeloma
*No disclosed MOA. We do not include details of trials without this basic information.*
NCT07426757 First-in-human - New trial Spotlight
Neuroendocrine and adrenal tumors
Phase 3 obrixtamig DLL3×CD3 bispecific T‑cell engager plus platinum/etoposide in DLL3+ epNEC
Boehringer Ingelheim’s multicenter, open-label, randomized Phase 3 trial (NCT07544654) tests whether adding obrixtamig—an IgG-like DLL3×CD3 bispecific antibody that redirects T cells to kill DLL3-expressing tumor…
NCT07544654 Registrational - New trial
Neuroendocrine and adrenal tumors
Phase 1 RYZ401 Actinium-225 SSTR2-targeted alpha radiopharmaceutical in SSTR+ tumors.
This first-in-human Phase 1, open-label dose-escalation and dose-expansion trial tests RYZ401, RayzeBio’s somatostatin receptor (SSTR2)-targeted peptide radiopharmaceutical labeled with actinium-225, an…
NCT07165132 First-in-human - New trial Spotlight
Stomach and esophageal cancer
Phase 2/3 PF-08634404 PD-1×VEGF bispecific antibody + chemo in 1L PD-L1+ HER2− GE cancers
Pfizer’s Phase 2/3, multicenter, interventional study tests PF-08634404—an investigational bispecific antibody that targets PD-1 (immune checkpoint) and VEGF (angiogenesis signaling)—given with standard first-line…
NCT07392892 Exploratory - New trial
Sarcoma and GIST
Phase 2 KQB198 + imatinib tests EGFR-targeted protein degrader in 1L metastatic GIST.
This Phase 2, multicenter, open-label study sponsored by Kumquat Biosciences evaluates KQB198 plus imatinib in participants with unresectable or metastatic gastrointestinal stromal tumor (GIST) receiving first-line…
NCT07406633 Exploratory - New trial
Sarcoma and GIST
Pilot Definity (perflutren lipid microspheres) CEUS microbubble perfusion/pressure imaging in STS RT
This single-site, open-label, non-randomized pilot at Thomas Jefferson University tests whether contrast-enhanced ultrasound (CEUS) can feasibly guide radiotherapy (RT) planning and predict response in patients with…
NCT07436364 Exploratory - New trial
Sarcoma and GIST
Phase 2 BMS-986504 MTA-cooperative PRMT5 inhibitor for MTAP-deleted MPNST
This Phase 2, open-label study evaluates BMS-986504 (navlimetostat), an MTA-cooperative PRMT5 inhibitor, as monotherapy in unresectable malignant peripheral nerve sheath tumor (MPNST) with homozygous MTAP deletion.…
NCT07549022 Exploratory - New trial
Lymphoma
Phase 1 KK2223 in R/R T-cell NHL (PTCL/CTCL)
*No disclosed MOA. We do not include details of trials without this basic information.*
NCT07192471 First-in-human - New trial
Lymphoma
Phase 2 mosunetuzumab CD20×CD3 bispecific antibody + pirtobrutinib noncovalent BTK inhibitor in R/R WM.
University of Utah’s MPOWER is a Phase 2, open-label study testing safety/tolerability and early activity of mosunetuzumab plus pirtobrutinib for relapsed/refractory Waldenström macroglobulinemia after prior covalent…
NCT07548450 Exploratory - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 3 bleximenib (JNJ-75276617) menin–KMT2A interaction inhibitor added to intensive AML chemo
This randomized, double-blind, placebo-controlled Phase 3 trial tests whether adding bleximenib (JNJ-75276617)—an oral small-molecule inhibitor of the menin–KMT2A protein interaction—improves outcomes when layered…
NCT07223814 Registrational - New trial
Acute myeloid leukemia and MDS
Phase 1 ruxolitinib JAK1/2 inhibitor plus azacitidine DNA hypomethylating agent after alloHSCT
This Phase 1, single-site OHSU Knight Cancer Institute study tests safety, tolerability, and dose selection for post-transplant ruxolitinib (a JAK1/2 inhibitor; marketed as Jakafi by Incyte) given first as…
NCT07548983 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 1 PLM-102 FLT3 inhibitor (next-generation tyrosine kinase inhibitor) in R/R AML/MDS
This Phase 1, open-label, dose-escalation study at MD Anderson Cancer Center is designed to define the maximum tolerated dose and recommended Phase 2 dose of PLM-102, an oral small-molecule FLT3 tyrosine kinase…
NCT07549464 Exploratory - New trial
Acute myeloid leukemia and MDS
Phase 2 imetelstat telomerase inhibitor in MDS/MPN overlap syndromes and CMML.
This Phase 2, single-arm MD Anderson study tests imetelstat, a first-in-class telomerase inhibitor (an oligonucleotide that binds the telomerase RNA template to block telomere maintenance), given by IV infusion every…
NCT07549451 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.